Answers are grounded in this paper and cite their sources.
// Yusuke Inoue 1, 2 , Katsuhiro Yoshimura 1, 2 , Kazutaka Mori 2 , Nobuya Kurabe 1 , Tomoaki Kahyo 1 , Hiroki Mori 3 , Akikazu Kawase 4 , Masayuki Tanahashi 5 , Hiroshi Ogawa 6 , Naoki Inui 2, 7 , Kazuhito Funai 4 , Kazuya Shinmura 1 , Hiroshi Niwa 5 , Takafumi Suda 2 , Haruhiko Sugimura 1 1 Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan 2 Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan 3 Department of Pathology, Hamamatsu Medical Center, Hamamatsu, Shizuoka, Japan 4 First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan 5 Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan 6 Department of Pathology, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan 7 Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan Correspondence to: Haruhiko Sugimura, email: hsugimur@hama-med.ac.jp Keywords: PD-L1, PD-L2, amplification, copy number, non-small-cell lung cancer Received: November 06, 2015 Accepted: February 24, 2016 Published: April 01, 2016 ABSTRACT New reliable biomarkers are needed to predict the response to immune checkpoint inhibitors against programmed death-1 (PD-1) and its ligand (PD-L1), because PD-L1 expression on tumor cells has limited power for selecting patients who may benefit from such therapy. Here we investigated the significance of PD-L1 and PD-L2 gene copy number gains using fluorescence in situ hybridization as well as PD-L1 and PD-L2 expression in 654 patients with resected non-small-cell lung cancer. The prevalence of PD-L1 amplification and polysomy was 3.1% and 13.2%, respectively. The PD-L1 gene copy number status was in agreement with both the PD-L2 and Janus kinase 2 gene copy number statuses. PD-L1 and PD-L2 expression was observed in 30.7% and 13.1%, respectively. Both PD-L1 copy number gains and expression were associated with smoking-related tumors. Tumor cells with PD-L1 genomic gains exhibited significantly higher levels of PD-L1 expression than those without, but PD-L2 copy number gains were not related to PD-L2 augmentation. PD-L1 gene amplification and polysomy were independently associated with PD-L1 expression, with high immune infiltrates and EGFR expression in a multivariate logistic regression model. Comparative analysis between primary tumors and synchronous regional lymph node metastases revealed that the PD-L1 gene copy number alterations were highly consistent and reproducible compared with the PD-L1 expression. Both PD-L1 amplification and level of protein expression were predictors of poor survival using Cox univariate analyses. Therefore, we conclude that an increase in PD-L1 gene copy number can be a feasible alternative biomarker for predicting response to anti-PD-1/PD-L1 therapy.
No takes yet. Share an insight, caveat, or question.
Inoue et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: